Cargando…

Risk factors of proteinuria in renal cell carcinoma patients treated with VEGF inhibitors: a secondary analysis of pooled clinical trial data

BACKGROUND: Proteinuria is a common adverse effect of vascular endothelial growth factor targeted agents, particularly in metastatic renal cell carcinoma (mRCC). However, risk factors for proteinuria are poorly defined. METHODS: Data on 1392 mRCC patients using pazopanib or sunitinib were pooled fro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sorich, Michael J, Rowland, Andrew, Kichenadasse, Ganessan, Woodman, Richard J, Mangoni, Arduino A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2016
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4984472/ https://www.ncbi.nlm.nih.gov/pubmed/27228299 http://dx.doi.org/10.1038/bjc.2016.147

Ejemplares similares

Predictors of anti-VEGF drug-induced hypertension using different hypertension criteria: a secondary analysis of the COMPARZ study
por: Mangoni, Arduino A., et al.
Publicado: (2018)

Risk factors for severe rash with use of vemurafenib alone or in combination with cobimetinib for advanced melanoma: pooled analysis of clinical trials
por: Hopkins, Ashley M., et al.
Publicado: (2020)

Early tumor shrinkage identifies long-term disease control and survival in patients with lung cancer treated with atezolizumab
por: Hopkins, Ashley M, et al.
Publicado: (2020)

Risk factors for MEK-associated retinopathy in patients with advanced melanoma treated with combination BRAF and MEK inhibitor therapy
por: Booth, Andrew E. C., et al.
Publicado: (2020)

C-reactive protein provides superior prognostic accuracy than the IMDC risk model in renal cell carcinoma treated with Atezolizumab/Bevacizumab
por: Abuhelwa, Ahmad Y., et al.
Publicado: (2022)

Machine Learning for Prediction of Survival Outcomes with Immune-Checkpoint Inhibitors in Urothelial Cancer
por: Abuhelwa, Ahmad Y., et al.
Publicado: (2021)

Predicting response and toxicity to immune checkpoint inhibitors using routinely available blood and clinical markers
por: Hopkins, Ashley M, et al.
Publicado: (2017)

Validation and Adaptation of the Multidimensional Prognostic Index in an Older Australian Cohort
por: Bryant, Kimberley, et al.
Publicado: (2019)

The Influence of Pre-Existing Beta-Blockers Use on Survival Outcomes in HER2 Positive Advanced Breast Cancer: Pooled Analysis of Clinical Trial Data
por: Modi, Natansh D., et al.
Publicado: (2020)

The obesity paradox in early and advanced HER2 positive breast cancer: pooled analysis of clinical trial data
por: Modi, Natansh D., et al.
Publicado: (2021)

Value of the Lung Immune Prognostic Index in Patients with Non-Small Cell Lung Cancer Initiating First-Line Atezolizumab Combination Therapy: Subgroup Analysis of the IMPOWER150 Trial
por: Hopkins, Ashley M., et al.
Publicado: (2021)

Reply to Auclin et al. Comment on “Hopkins et al. Value of the Lung Immune Prognostic Index in Patients with Non-Small Cell Lung Cancer Initiating First-Line Atezolizumab Combination Therapy: Subgroup Analysis of the IMPOWER150 Trial. Cancers 2021, 13, 1176”
por: Hopkins, Ashley M., et al.
Publicado: (2021)

Artificial intelligence chatbots will revolutionize how cancer patients access information: ChatGPT represents a paradigm-shift
por: Hopkins, Ashley M, et al.
Publicado: (2023)

Optimized Cocktail Phenotyping Study Protocol Using Physiological Based Pharmacokinetic Modeling and In silico Assessment of Metabolic Drug–Drug Interactions Involving Modafinil
por: Rowland, Angela, et al.
Publicado: (2016)

Advanced Diabetic Nephropathy with Nephrotic Range Proteinuria: A Pilot Study of the Long-Term Efficacy of Subcutaneous ACTH Gel on Proteinuria, Progression of CKD, and Urinary Levels of VEGF and MCP-1
por: Tumlin, J. A., et al.
Publicado: (2013)

Use of Multiprognostic Index Domain Scores, Clinical Data, and Machine Learning to Improve 12-Month Mortality Risk Prediction in Older Hospitalized Patients: Prospective Cohort Study
por: Woodman, Richard John, et al.
Publicado: (2021)

Reply: Comment on ‘Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal-antibody therapy for RAS wild-type metastatic colorectal cancer'
por: Rowland, Andrew, et al.
Publicado: (2015)

Targeted pharmacotherapy after somatic cancer mutation screening
por: Polasek, Thomas M., et al.
Publicado: (2016)

Nuances to precision dosing strategies of targeted cancer medicines
por: Hopkins, Ashley M., et al.
Publicado: (2020)

Outcomes of normotensive IgA nephropathy patients with mild proteinuria who have impaired renal function
por: Tan, Min, et al.
Publicado: (2019)

A comprehensive review of machine learning algorithms and their application in geriatric medicine: present and future
por: Woodman, Richard J., et al.
Publicado: (2023)

Sorafenib tolerability in elderly patients with advanced renal cell carcinoma: results from a large pooled analysis
por: Procopio, G, et al.
Publicado: (2013)

The Effects of Helicobacter pylori Eradication on Proteinuria in Patients with Primary Glomerulonephritis
por: Caliskan, Bahar, et al.
Publicado: (2014)

Baseline proteinuria level is associated with prognosis in idiopathic membranous nephropathy
por: Chen, Xinxin, et al.
Publicado: (2019)

The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma
por: Shroff, Rachna T, et al.
Publicado: (2017)

Tumour shrinkage measured with first treatment evaluation under VEGF-targeted therapy as prognostic marker in metastatic renal cell carcinoma (mRCC)
por: Seidel, C, et al.
Publicado: (2013)

Protocol for the Flinders Kidney Health Registry: patient outcomes of kidney cancers and nephrectomies
por: Li, Jordan Y., et al.
Publicado: (2022)

Predictors of survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery based on the pooled analysis of an international collaborative cohort
por: Zang, R Y, et al.
Publicado: (2011)

Glomerulosclerosis is a prognostic risk factor in patients with membranous nephropathy and non-nephrotic proteinuria
por: Sun, Jing, et al.
Publicado: (2023)

Phase II randomised discontinuation trial of the MET/VEGF receptor inhibitor cabozantinib in metastatic melanoma
por: Daud, Adil, et al.
Publicado: (2017)

Prognostic value of the 7-year protocol biopsy of adult kidney allografts: impact of mesangiosclerosis and proteinuria
por: Itabashi, Yoshihiro, et al.
Publicado: (2023)

Determinants of visual acuity outcomes in eyes with neovascular AMD treated with anti-VEGF agents: an instrumental variable analysis of the AURA study
por: Holz, F G, et al.
Publicado: (2016)

Clinical and pathologic characteristics of pauci-immune anti-myeloperoxidase antibody associated glomerulonephritis with nephrotic range proteinuria
por: Xu, Peng-Cheng, et al.
Publicado: (2018)

Preoperative proteinuria may be a risk factor for postoperative acute kidney injury：a meta-analysis
por: Huang, Dan-Dan, et al.
Publicado: (2021)

Quality of life in patients with advanced renal cell carcinoma treated with temsirolimus or interferon-α
por: Yang, S, et al.
Publicado: (2010)

Clinicopathological Features of Gitelman Syndrome with Proteinuria and Renal Dysfunction
por: Zhang, Lei, et al.
Publicado: (2023)

Serum VEGF-D level is correlated with renal dysfunction and proteinuria in patients with diabetic chronic kidney disease
por: Nguyen, Thi Thuy Uyen, et al.
Publicado: (2022)

Severe Proteinuria Secondary to Amyloidosis Requiring Bilateral Renal Artery Embolization
por: Yeh, Chun-Tung, et al.
Publicado: (2012)

Prognostic factors for survival in 1059 patients treated with sunitinib for metastatic renal cell carcinoma
por: Motzer, R J, et al.
Publicado: (2013)

Effect of Omega-3 Fatty Acid on the Fatty Acid Content of the Erythrocyte Membrane and Proteinuria in Patients with Diabetic Nephropathy
por: Lee, Su Mi, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_dlbsl8nrehj54e3u2rslms6mia